Common use of Specimen Analysis Clause in Contracts

Specimen Analysis. 1.5.1 CONTRACTOR shall perform full screening and confirmation of one (1) of the following panels for each CLIENT as requested by ADMINISTRATOR via Aversys.‌ Panel #1, SSA Standard Drug Panel, including marijuana, cocaine, expanded opiates (morphine, heroin, hydrocodone, hydromorphone, oxycodone, and oxymorphone), phencyclidine, amphetamines, barbiturates, benzodiazepines, methadone,‌ propoxyphene, and alcohol. Panel #2, Illicit Drug Panel Plus ethyl glucuronide (ETG) test, including cocaine, amphetamines, opiates, marijuana, benzodiazepines and ETG. Panel #3, Opioids, including benzodiazepines, buprenorphine, cocaine, rotation of fentanyl (34%), meperidine (33%) and tramadol (33%), opiates, oxycodone and marijuana.‌ Panel #4, Synthetic THC. 1.5.2 CONTRACTOR shall, conduct a Breath Alcohol Content (BAC) test at no additional cost to COUNTY, on all CLIENTS that report to “In County” and Avertest LLC, dba Averhealth Owned and Operated “Out of County” client service centers and conduct an ETG test on all CLIENT samples submitted at an “Out of County / Avertest LLC dba Averhealth In-Network Facility.” 1.5.3 CONTRACTOR shall add, upon electronic request by ADMINISTRATOR, any one (1) or more of the following Specialty Drug Add-Ons to any of the test panels described above in Subparagraphs 1.5. 1.1 through 1.5.1.3 of Exhibit C: buprenorphine, carisoprodol, ETG, gabapentin, heroin (specific immunoassay test), ketamine, Lysergic Acid Diethylamide (LSD), meperidine, neurontin, tramadol, or zolpidem. 1.5.4 CONTRACTOR shall allow ADMINISTRATOR to order, within Aversys, customized test panels of varying substances, as needed, to meet CLIENTS’ needs as determined by ADMINISTRATOR. At the sole discretion of ADMINISTRATOR, such test panels may replace, for either groups or individuals, any test panel described above in Subparagraphs 1.5.1.1 through 1.5.1.3 of Exhibit C. Pricing for customized panels shall be at CONTRACTOR’s catalog price. 1.5.5 CONTRACTOR acknowledges that ADMINISTRATOR has the option to rotate panels described in Subparagraph 1.5.1 of Exhibit C. 1.5.6 CONTRACTOR shall ensure specimen integrity by visually inspecting all samples to evaluate color and clarity, and evaluating the specimen potential of hydrogen (pH) to ascertain that it falls within an acceptable range. Each drug screen shall include creatinine and nitrite level tests to check for dilution and commercial adulterants. 1.5.7 CONTRACTOR shall test specimens with creatinine values less than 20.0 mg/dl and greater than 5.0 mg/dl for specific gravity using a three (3) decimal place refractometer on the initial aliquot. Specimens with creatinine in the range of 5.1 – 19.9 mg/dl and specific gravity equal to 1. 002 shall be reported as dilute. 1.5.8 CONTRACTOR shall ensure all urine specimens are tested exclusively by a laboratory certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) or accredited by the College of American Pathologists for Forensic Drug Testing (CAP-FDT). Maintain certification of laboratory by SAMHSA or accreditation by the CAP-FDT, thus making the laboratory authorized for urine specimen testing under this Agreement. 1.5.9 The minimum drug screening sensitivity limits are as follows:‌ Drug/Metabolite Ng/mL Screening(1) Ng/mL (LC MS/MS)(2) Marijuana Metabolite 20 5 Cocaine Metabolite 300 25 Opiates: 300 N/A Morphine 50 Codeine 50 6-Acetylmorphine 5 Expanded Opiates: Hydrocodone 50 Hydromorphone 50 Oxycodone 50 Phencyclidine (PCP) 25 12 Amphetamine: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇/▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇/▇ 125 MDMA (Ecstasy) 50 Barbiturates: 200 Amobarbital 100 Butalbital 100 Pentobarbital 100 Phenobarbital 100 Secobarbital 100 Benzodiazepines: 200 Alprazolam Metabolite 50 Triazolam Metabolite 50 Flurazepam Metabolite 50 Lorazepam 50 Nordiazepam 50 Oxazepam 50 Temazepam 50 Methadone 300 25 Propoxyphene: 300 25 (1) Nanograms per milliliter

Specimen Analysis. 1.5.1 CONTRACTOR shall perform full screening and confirmation of one (1) of the following panels for each CLIENT as requested by ADMINISTRATOR via Aversys.‌ Aversys. Panel #1, SSA Standard Drug Panel, including marijuana, cocaine, expanded opiates (morphine, heroin, hydrocodone, hydromorphone, oxycodone, and oxymorphone), phencyclidine, amphetamines, barbiturates, benzodiazepines, methadone,‌ methadone, propoxyphene, and alcohol. Panel #2, Illicit Drug Panel Plus ethyl glucuronide (ETG) test, including cocaine, amphetamines, opiates, marijuana, benzodiazepines and ETG. Panel #3, Opioids, including benzodiazepines, buprenorphine, cocaine, rotation of fentanyl (34%), meperidine (33%) and tramadol (33%), opiates, oxycodone and marijuana.‌ marijuana. Panel #4, Synthetic THC. 1.5.2 CONTRACTOR shall, conduct a Breath Alcohol Content (BAC) test at no additional cost to COUNTY, on all CLIENTS that report to “In County” and Avertest LLC, dba Averhealth Owned and Operated “Out of County” client service centers and conduct an ETG test on all CLIENT samples submitted at an “Out of County / Avertest LLC dba Averhealth In-Network Facility.” 1.5.3 CONTRACTOR shall add, upon electronic request by ADMINISTRATOR, any one (1) or more of the following Specialty Drug Add-Ons to any of the test panels described above in Subparagraphs 1.5. 1.1 through 1.5.1.3 of Exhibit C: buprenorphine, carisoprodol, ETG, gabapentin, heroin (specific immunoassay test), ketamine, Lysergic Acid Diethylamide (LSD), meperidine, neurontin, tramadol, or zolpidem. 1.5.4 CONTRACTOR shall allow ADMINISTRATOR to order, within Aversys, customized test panels of varying substances, as needed, to meet CLIENTS’ needs as determined by ADMINISTRATOR. At the sole discretion of ADMINISTRATOR, such test panels may replace, for either groups or individuals, any test panel described above in Subparagraphs 1.5.1.1 through 1.5.1.3 of Exhibit C. Pricing for customized panels shall be at CONTRACTOR’s catalog price. 1.5.5 CONTRACTOR acknowledges that ADMINISTRATOR has the option to rotate panels described in Subparagraph 1.5.1 of Exhibit C. 1.5.6 CONTRACTOR shall ensure specimen integrity by visually inspecting all samples to evaluate color and clarity, and evaluating the specimen potential of hydrogen (pH) to ascertain that it falls within an acceptable range. Each drug screen shall include creatinine and nitrite level tests to check for dilution and commercial adulterants. 1.5.7 CONTRACTOR shall test specimens with creatinine values less than 20.0 mg/dl and greater than 5.0 mg/dl for specific gravity using a three (3) decimal place refractometer on the initial aliquot. Specimens with creatinine in the range of 5.1 – 19.9 mg/dl and specific gravity equal to 1. 002 shall be reported as dilute. 1.5.8 CONTRACTOR shall ensure all urine specimens are tested exclusively by a laboratory certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) or accredited by the College of American Pathologists for Forensic Drug Testing (CAP-FDT). Maintain certification of laboratory by SAMHSA or accreditation by the CAP-FDT, thus making the laboratory authorized for urine specimen testing under this Agreement. 1.5.9 The minimum drug screening sensitivity limits are as follows:‌ follows: Drug/Metabolite Ng/mL Screening(1) Ng/mL (LC MS/MS)(2) Marijuana Metabolite 20 5 Cocaine Metabolite 300 25 Opiates: 300 N/A Morphine 50 Codeine 50 6-Acetylmorphine 5 Expanded Opiates: Hydrocodone 50 Hydromorphone 50 Oxycodone 50 Phencyclidine (PCP) 25 12 Amphetamine: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇/▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇/▇ 125 MDMA (Ecstasy) 50 Barbiturates: 200 Amobarbital 100 Butalbital 100 Pentobarbital 100 Phenobarbital 100 Secobarbital 100 Benzodiazepines: 200 Alprazolam Metabolite 50 Triazolam Metabolite 50 Flurazepam Metabolite 50 Lorazepam 50 Nordiazepam 50 Oxazepam 50 Temazepam 50 Methadone 300 25 Propoxyphene: 300 25 (1) Nanograms per milliliter